Abstract 1885P
Background
Pexa-vec (PV) is an oncolytic and immunotherapeutic vaccinia virus engineered to express GM-CSF. The REN026 study assessed the antitumor activity and safety of intravenous (IV) or intratumoral(IT) PV in combination with cemiplimab (REGN2810, anti-PD-1 inhibitor) in patients with metastatic or unresectable renal cell carcinoma (RCC).
Methods
The study enrolled 89 patients with measurable histologically or cytologically confirmed metastatic or unresectable RCC, randomly assigned to one of four study arms. Patients who were treatment-naive to immune check point inhibitors (ICIs) with accessible tumors were randomized into Arm A (IT PV and cemiplimab) or Arm B (cemiplimab monotherapy, upon disease progression PV (IT) was added. Patients who were treatment-naïve to ICIs with non-accessible tumors were assigned to Arm C with IV PV, and those with prior treatment with ICIs were assigned to Arm D with IV PV. PV was given IT (Arms A and B) administered every 2 weeks or IV (Arms C and D) weekly for 3 or 4 treatments as 1× 109 pfu. Cemiplimab IV infusion (all arms) was administered every 3 weeks, at a dose of 350 mg.
Results
Between June 2018 and October 2022, 89 patients were assigned to the study arms as follows: 15 in Arm A, 16 in Arm B, 30 in Arm C, and 28 in Arm D. The median number of prior systemic regimens in the metastatic setting was 1 (0-4) in Arms A, B, and C and 3 (1-5) in Arm D. With the median follow-up of 22.2 months, efficacy outcomes are shown in table. The most common treatment-related adverse event was pyrexia, with a Grade ≥ 3 of 13.3% in Arm A, 0% in Arm B,0% in Arm C, and 3.6% in Arm D. No Grade 5 events occurred in any of the study arms. Table: 1885P
Summary of efficacy results
| A (n=15) | B (n=16) | C (n=30) | D (n=28) | |
| IT | IV | |||
| ORR (95% CI)-% | 13.3 (1.7-40.5) | 12.5 (1.6-38.4) | 23.3 (9.9-42.3) | 17.9 (6.1-36.9) |
| DCR (95% CI)-% | 60.0 (32.3-83.7) | 56.2 (29.9-80.3) | 60.0 (40.6-77.3) | 67.9 (47.7-84.1) |
| PFS median (mo) (80% CI) | 4.3 (3.3-6.3) | 5.6 (2.1-NA) | 4.8 (4.4-8.3) | 6.4 (3.6-12.3) |
| OS median (mo) (80% CI) | 22.0 (22.0-NE) | 20.8 (19.5-NE) | 25.1 (22.7-NE) | 18.5 (14.8-NE) |
| Median duration of response (range,months) | 6.1 (3.7-8.5) | 7.7 (4.1-11.3) | 10.4 (5.5-24.1) | 8.5 (1.1-11.3) |
Conclusions
The combination immunotherapy of IV PV and cemiplimab demonstrated an acceptable safety profile and encouraging efficacy of ORR and survival with durable responses in patients with metastatic or unresectable RCC, regardless of previous ICI treatment.
Clinical trial identification
NCT03294083.
Editorial acknowledgement
Acknowledgments: None
Legal entity responsible for the study
SillaJen Inc.
Funding
SillaJen Inc
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23